Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suxiao Jiuxin Wan for endothelial protection in acute coronary syndrome
ChiCTR2100052583Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Dec 2021
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Suxiao Jiuxin Pills in acute coronary syndrome (ACS) and endothelial dysfunction (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: endothelium dependent dilation. Started Dec 2021; status: recruiting.
02
Drugs
Suxiao Jiuxin Pills
03
Conditions
acute coronary syndrome (ACS)endothelial dysfunction
Beyond the preview
Go deeper on ChiCTR2100052583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052583.